Foley partner Kyle Faget, co-chair of the Medical Devices & Equipment Area of Focus within the firm’s Health Care & Life Sciences Sector, is speaking on the panel “Exploring the Subtleties and Safe Zones of Off-Label Communications — Part 2” during the American Conference Institute’s FDA Boot Camp program on Thursday, March 26.
Medical and market access teams must inform without implying. This session delineates scientific exchange, health economics and outcomes research (HEOR), and payer communications so field conversations support care and the brand without drifting into misbranding.
Topics of discussion include:
- Differentiating scientific-exchange lanes and structuring medical-information responses.
- Deploying HEOR and safety communications and maintaining alignment with evidence.
- Anticipating attorney-general and plaintiff scrutiny and reducing litigation exposure.
Related Insights
April 24, 2026
Manufacturing Industry Advisor
FCA v. Kamax: Michigan Supreme Court Dismisses Appeal and Leaves Uncertainty for Automotive Manufacturers
On April 22, 2026, the Michigan Supreme Court entered an order dismissing the appeal of FCA US LLC v. Kamax Inc., a case of considerable…
April 24, 2026
Energy Current
The New Energy Trade War: Why Every CEO Must Rethink Their Power Strategy Now
For decades, energy strategy was something most CEOs could comfortably delegate. Procurement teams negotiated utility contracts,…
April 24, 2026
Foley Viewpoints
Justices Appear Skeptical of Investor-Harm Requirement in Sripetch SEC Disgorgement Case
On April 20, 2026, the Supreme Court heard oral arguments in Sripetch v. SEC, a case in which the Justices will answer whether the Securities and Exchange Commission must prove pecuniary harm to investors before a court can order disgorgement.